Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Smartwatch-Guided exercise may tame pregnancy risks

NCT ID NCT07678944

Disease control Sponsor: Unidade Local de Saúde de Coimbra, EPE Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 01, 2026 · Last updated Jul 02, 2026 · Updated 1 time

Summary

This study investigates whether a structured, personalized exercise plan—tracked with a smartwatch and supported by regular phone check-ins—can help control blood sugar, blood pressure, and weight gain in pregnant women with gestational diabetes, chronic hypertension, or obesity. Researchers compare outcomes between women who follow the exercise guidelines and those who do not. The goal is to see if this approach reduces complications like preterm birth and low birth weight.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
personalized exercise prescription with smartwatch monitoring
What this could lead to
If effective, this approach could offer a drug-free way to manage complications like gestational diabetes and hypertension during pregnancy, improving outcomes for both mother and baby.
What could go wrong
This is a single-arm study without a control group, so results may be influenced by other factors. Adherence to exercise may vary, and the findings may not apply to all pregnant women.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

310 people

The number who actually took part.

Started

Feb 2024

Finished

Aug 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

16 years and older

Sex

Female participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Pregnant women aged 16 years or older with a confirmed diagnosis of gestational diabetes (fasting blood glucose greater than 92 mg/dL in first trimester; or values in the oral glucose tolerance test in second trimester greater than 92/180/153 mg/dL, respectively at 0 hours, 1 hour after glucose ingestion, and 2 hours after) * Pregnant women aged 16 or older with chronic hypertension or a history of bariatric surgery and pre-pregnancy Body Mass Index (BMI) above 30Kg/m2. * Eligibility further required consistent clinical adherence defined as attending all schedule appointments with the obstetric team without unjustified absences Exclusion Criteria: * multiple gestations * risk of preterm labor * history of premature delivery due to a non-maternal cause * persistent vaginal bleeding * placenta previa beyond 28 weeks' gestation * cervical insufficiency * any limiting systemic, respiratory or cardiovascular disease.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Chronic hypertension are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

gestational diabetes hypertension, pregnancy-induced hypertensive disorder Obesity obesity disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Diabetes during pregnancy Hypertension ,pregnancy Obesity (bmi>30)

Contacts and locations

Locations

  • ULSCoimbra

    Coimbra, Coimbra District, 3004-561, Portugal

More trials for these conditions

Other studies related to the condition(s) this trial covers.